Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The CHARIOT Trial has officially received OCTRU Green Light approval. Churchill Hospital, Oxford will be the first recruiting site to open, following their local green light checks, and recruitment is expected to commence in November 2018. The trial will run across 5 UK sites.

CHARIOT is an interventional, phase I, open label, multicentre, 3-stage, schedule finding trial using time to event continual reassessment method (TiTE-CRM). This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer and other solid cancers in both palliative and definitive treatment. Stage A1 (M6620 + palliative radiotherapy) and A2 (M6620 + palliative chemotherapy (cisplatin/capecitabine)), both in patients with advanced inoperable oesophageal cancer, will run parallel to one another, followed by Stage B (M6620 in combination with cisplatin/capecitabine and radical radiotherapy) in patients with oesophageal tumours for radical chemoradiotherapy. Stage B will commence once sufficient data is collected from stages A1 and A2. 

CHARIOT is sponsored by the University of Oxford, funded by CRUK (C43735/A20874) and Merck KGaA, and managed by the Oncology Clinical Trials Office (OCTO). Statistical support is provided by the Centre for Statistics in Medicine (CSM). The Chief Investigator is Professor Maria Hawkins.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.